Offering ease of mobility and self-driving capabilities, the Ciartic Move C-arm device reportedly reduces the stress and potential for error associated with manual repositioning during intraoperative imaging with computed tomography and fluoroscopy.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the Ciartic Move C-arm device, which facilitate enhanced efficiency with intraoperative fluoroscopic and 3D cone-beam computed tomography (CT) imaging in the OR.
Providing full motorization from the C-arm down to the wheels of the device, the Ciartic Move has self-driving capabilities that may enable better consistency with intraoperative imaging and more automated imaging workflows, according to Siemens Healthineers, the manufacturer of the Ciartic Move.
Noting the device’s ability to reduce the time and workforce capacity associated with manual adjustments of conventional C-arm devices, Siemens Healthineers pointed out that the Ciartic Move device allows clinicians to store up to 12 procedure-specific positions with associated imaging parameters.
“With the FDA clearance of the Ciartic Move, Siemens Healthineers proudly introduces our first self-driving mobile C-arm, which can provide much-needed relief for overtaxed operating room teams by automating and accelerating intraoperative imaging workflows to a previously unseen degree,” said April Grandominico, vice president for surgical therapies in the Advanced Therapies business at Siemens Healthineers North America.
Can AI Facilitate Single-Phase CT Acquisition for COPD Diagnosis and Staging?
December 12th 2024The authors of a new study found that deep learning assessment of single-phase CT scans provides comparable within-one stage accuracies to multiphase CT for detecting and staging chronic obstructive pulmonary disease (COPD).
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.